Delayed creatine kinase elevation after sonidegib therapy in a patient with decompensated cirrhosis and esophagogastric variceal hemorrhage: A case report

Sonidegib, a hedgehog pathway inhibitor targeting the smoothened receptor, is widely used in advanced basal cell carcinoma (BCC). Creatine kinase (CK) elevation is a recognized adverse event following treatment with sonidegib, but its safety in patients with decompensated cirrhosis remains unclear. The present study reports the case of a 77‑year‑old man with chronic hepatitis B‑related decompensated cirrhosis who developed CK elevation after sonidegib therapy for locally advanced BCC. The patient had received oral sonidegib at 200 mg/day for 35 days, which was discontinued due to worsening ascites. Shortly afterward, the patient experienced esophagogastric variceal hemorrhage and was admitted to the Department of Hepatology at Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine (Shanghai China). At 4 days post‑admission (day 4) and 7 days after sonidegib discontinuation, CK was first found to be elevated to 3,291 U/l. The CK level peaked at 11,944 U/l on day 6, accompanied by elevated myoglobin, but without evidence of acute myocardial injury or renal impairment. Hypovolemia, electrolyte abnormality, critical disease‑associated myopathy, occult infection and concomitant medication were assessed as alternative or contributing explanations. A Naranjo Adverse Drug Reaction Probability Scale score of 4 indicated a possible adverse drug reaction. The patient received intravenous fluid replacement, permanent withdrawal of sonidegib and close monitoring. The CK level returned to the reference range by day 21, and the myoglobin level normalized by day 57; both remained normal during the 3 months of follow‑up. This case is notable for the delayed severe CK elevation after sonidegib discontinuation in the combined setting of decompensated cirrhosis and acute variceal bleeding, and highlights the importance and need for close and extended CK monitoring, careful assessment of hepatic function, and individualized treatment decisions in patients with cirrhosis receiving sonidegib.

Authors

Institutions

Publication Details

Journal
Experimental and Therapeutic Medicine
Published
2026-11-16
DOI
https://doi.org/10.3892/etm.2026.13357
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Delayed creatine kinase elevation after sonidegib therapy in a patient with decompensated cirrhosis and esophagogastric variceal hemorrhage: A case report

Yunhui Zhuo, Bowu Chen, Binyi Shang, Yanxi Zheng et al.
1 links
Experimental and Therapeutic Medicine
Pharmacovigilance and Adverse Drug Reactions
article

Delayed creatine kinase elevation after sonidegib therapy in a patient with decompensated cirrhosis and esophagogastric variceal hemorrhage: A case report

Yunhui Zhuo, Bowu Chen, Binyi Shang, Yanxi Zheng, Shuting Zhuang
article en

Abstract

Sonidegib, a hedgehog pathway inhibitor targeting the smoothened receptor, is widely used in advanced basal cell carcinoma (BCC). Creatine kinase (CK) elevation is a recognized adverse event following treatment with sonidegib, but its safety in patients with decompensated cirrhosis remains unclear. The present study reports the case of a 77‑year‑old man with chronic hepatitis B‑related decompensated cirrhosis who developed CK elevation after sonidegib therapy for locally advanced BCC. The patient had received oral sonidegib at 200 mg/day for 35 days, which was discontinued due to worsening ascites. Shortly afterward, the patient experienced esophagogastric variceal hemorrhage and was admitted to the Department of Hepatology at Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine (Shanghai China). At 4 days post‑admission (day 4) and 7 days after sonidegib discontinuation, CK was first found to be elevated to 3,291 U/l. The CK level peaked at 11,944 U/l on day 6, accompanied by elevated myoglobin, but without evidence of acute myocardial injury or renal impairment. Hypovolemia, electrolyte abnormality, critical disease‑associated myopathy, occult infection and concomitant medication were assessed as alternative or contributing explanations. A Naranjo Adverse Drug Reaction Probability Scale score of 4 indicated a possible adverse drug reaction. The patient received intravenous fluid replacement, permanent withdrawal of sonidegib and close monitoring. The CK level returned to the reference range by day 21, and the myoglobin level normalized by day 57; both remained normal during the 3 months of follow‑up. This case is notable for the delayed severe CK elevation after sonidegib discontinuation in the combined setting of decompensated cirrhosis and acute variceal bleeding, and highlights the importance and need for close and extended CK monitoring, careful assessment of hepatic function, and individualized treatment decisions in patients with cirrhosis receiving sonidegib.

Experimental and Therapeutic MedicineVol. 33(1)
Shanghai University of Traditional Chinese Medicine (CN), Shuguang Hospital (CN)
Shanghai Municipal Health Commission, Shanghai University of Traditional Chinese Medicine
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon